Zavante Therapeutics Report issue

For profit Phase 3
Founded: San Diego CA United States (2015)
Status: Acquired by Nabriva Therapeutics AG (2018)

Organization Overview

First Clinical Trial
2016
NCT02753946
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

fosfomycin (monurol) (1 trial)

piperacillin (pipracil) (1 trial)

tazobactam (Zosyn) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Infections (Phase 3)

Pyelonephritis (Phase 3)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3